CME Supplements

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

• Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
• Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
• Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
• Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

Click here to read the supplement.

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

• Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
• Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
• Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
• Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

Click here to read the supplement.

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

• Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
• Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
• Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
• Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

Click here to read the supplement.

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

One-third of patients who visit a gynecologist are there because of abnormal uterine bleeding (AUB), which is believed to account for more than 70% of gyneco¬logic consults in perimenopausal and postmenopausal women. The American College of Obstetricians and Gynecologists Practice Bulle¬tin on AUB now states that a negative blind endometrial biopsy is not a stopping point in persistent bleeding.

In this supplement, learn about the advantages of diagnosing AUB using a hysteroscope.

Authors:

Steven R. Goldstein, MD, CCD, NCMP, FACOG

New York University Medical Center New York, New York

Ted L. Anderson, MD, PhD

Vanderbilt University Medical School Nashville, Tennessee

 

Click here to read this supplement.

To access the posttest and evaluation, visit
www.worldclasscme.com/endometrialevaluation

One-third of patients who visit a gynecologist are there because of abnormal uterine bleeding (AUB), which is believed to account for more than 70% of gyneco¬logic consults in perimenopausal and postmenopausal women. The American College of Obstetricians and Gynecologists Practice Bulle¬tin on AUB now states that a negative blind endometrial biopsy is not a stopping point in persistent bleeding.

In this supplement, learn about the advantages of diagnosing AUB using a hysteroscope.

Authors:

Steven R. Goldstein, MD, CCD, NCMP, FACOG

New York University Medical Center New York, New York

Ted L. Anderson, MD, PhD

Vanderbilt University Medical School Nashville, Tennessee

 

Click here to read this supplement.

To access the posttest and evaluation, visit
www.worldclasscme.com/endometrialevaluation

One-third of patients who visit a gynecologist are there because of abnormal uterine bleeding (AUB), which is believed to account for more than 70% of gyneco¬logic consults in perimenopausal and postmenopausal women. The American College of Obstetricians and Gynecologists Practice Bulle¬tin on AUB now states that a negative blind endometrial biopsy is not a stopping point in persistent bleeding.

In this supplement, learn about the advantages of diagnosing AUB using a hysteroscope.

Authors:

Steven R. Goldstein, MD, CCD, NCMP, FACOG

New York University Medical Center New York, New York

Ted L. Anderson, MD, PhD

Vanderbilt University Medical School Nashville, Tennessee

 

Click here to read this supplement.

To access the posttest and evaluation, visit
www.worldclasscme.com/endometrialevaluation

Mauricio Tohen, MD, DrPH, MBA 
Professor and Chair
Department of Psychiatry and Behavioral Sciences
University of New Mexico School of Medicine
Albuquerque, New Mexico 

Claudia Baldassano, MD 
Associate Professor of Psychiatry
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 

Vladimir Maletic, MD, MS 
Clinical Professor of Neuropsychiatry and Behavioral Science
University of South Carolina School of Medicine
Greenville, South Carolina

Consulting Associate
Division of Child and Adolescent Psychiatry Department of Psychiatry
Duke University
Durham, North Carolina

Click here to read the supplement

After reading, visit https://MERdepression.cvent.com to complete the posttest and evaluation for CME/CE credit.

Mauricio Tohen, MD, DrPH, MBA 
Professor and Chair
Department of Psychiatry and Behavioral Sciences
University of New Mexico School of Medicine
Albuquerque, New Mexico 

Claudia Baldassano, MD 
Associate Professor of Psychiatry
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 

Vladimir Maletic, MD, MS 
Clinical Professor of Neuropsychiatry and Behavioral Science
University of South Carolina School of Medicine
Greenville, South Carolina

Consulting Associate
Division of Child and Adolescent Psychiatry Department of Psychiatry
Duke University
Durham, North Carolina

Click here to read the supplement

After reading, visit https://MERdepression.cvent.com to complete the posttest and evaluation for CME/CE credit.

Mauricio Tohen, MD, DrPH, MBA 
Professor and Chair
Department of Psychiatry and Behavioral Sciences
University of New Mexico School of Medicine
Albuquerque, New Mexico 

Claudia Baldassano, MD 
Associate Professor of Psychiatry
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania 

Vladimir Maletic, MD, MS 
Clinical Professor of Neuropsychiatry and Behavioral Science
University of South Carolina School of Medicine
Greenville, South Carolina

Consulting Associate
Division of Child and Adolescent Psychiatry Department of Psychiatry
Duke University
Durham, North Carolina

Click here to read the supplement

After reading, visit https://MERdepression.cvent.com to complete the posttest and evaluation for CME/CE credit.

This supplement includes 2 CME credits. (scroll down)

Topics include:

• Biologics, Biosimilars, and Generics
• Community-Acquired Bacterial Pneumonia
• Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus
• Dual therapy for Type 2 Diabetes Mellitus
• GLP-1R Agonists
• Medication Adherence in Type 2 Diabetes Mellitus
• NSAIDs
• Sublingual Immunotherapy

This supplement offers the opportunity to earn a total of 2 CME credits. 

Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.

• Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/liver.
• Role of the Microbiome in Disease: Implications for Treatment of Irritable Bowel Syndrome
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/microbiome.

This supplement includes 2 CME credits. (scroll down)

Topics include:

• Biologics, Biosimilars, and Generics
• Community-Acquired Bacterial Pneumonia
• Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus
• Dual therapy for Type 2 Diabetes Mellitus
• GLP-1R Agonists
• Medication Adherence in Type 2 Diabetes Mellitus
• NSAIDs
• Sublingual Immunotherapy

This supplement offers the opportunity to earn a total of 2 CME credits. 

Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.

• Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/liver.
• Role of the Microbiome in Disease: Implications for Treatment of Irritable Bowel Syndrome
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/microbiome.

This supplement includes 2 CME credits. (scroll down)

Topics include:

• Biologics, Biosimilars, and Generics
• Community-Acquired Bacterial Pneumonia
• Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus
• Dual therapy for Type 2 Diabetes Mellitus
• GLP-1R Agonists
• Medication Adherence in Type 2 Diabetes Mellitus
• NSAIDs
• Sublingual Immunotherapy

This supplement offers the opportunity to earn a total of 2 CME credits. 

Credit is awarded for successful completion of the online evaluations at the links below; these links may also be found within the supplement on the first page of each article.

• Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/liver.
• Role of the Microbiome in Disease: Implications for Treatment of Irritable Bowel Syndrome
  • To complete the online evaluation and receive 1 CME credit for this article: please click on the link at the end of the article or go to http://www.pceconsortium.org/microbiome.

• Be comfortable taking a sexual history from their patients.
• Understand the prevalence of HSDD.
• Understand how to diagnose HSDD and distinguish it from other sexual complaints.
• Understand data from trials involving pharmacologic agents both approved and not approved in attempts to treat HSDD.
• Employ multidisciplinary communication strategies to improve quality of life in patients with PDP

This CME supplement entitles the reader to 1 free CME credit.

Click here to read supplement.

After reading the supplement, click here to access the CME posttest 

• Be comfortable taking a sexual history from their patients.
• Understand the prevalence of HSDD.
• Understand how to diagnose HSDD and distinguish it from other sexual complaints.
• Understand data from trials involving pharmacologic agents both approved and not approved in attempts to treat HSDD.
• Employ multidisciplinary communication strategies to improve quality of life in patients with PDP

This CME supplement entitles the reader to 1 free CME credit.

Click here to read supplement.

After reading the supplement, click here to access the CME posttest 

• Be comfortable taking a sexual history from their patients.
• Understand the prevalence of HSDD.
• Understand how to diagnose HSDD and distinguish it from other sexual complaints.
• Understand data from trials involving pharmacologic agents both approved and not approved in attempts to treat HSDD.
• Employ multidisciplinary communication strategies to improve quality of life in patients with PDP

This CME supplement entitles the reader to 1 free CME credit.

Click here to read supplement.

After reading the supplement, click here to access the CME posttest 

After reading this CME supplement, health care providers will have improved their ability to:

This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™
Click here to read supplement. 
After reading the supplement, click here to access the CME posttest

After reading this CME supplement, health care providers will have improved their ability to:

This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™
Click here to read supplement. 
After reading the supplement, click here to access the CME posttest

After reading this CME supplement, health care providers will have improved their ability to:

This CME supplement entitles the reader to 1.0 AMA PRA Category 1 Credit™
Click here to read supplement. 
After reading the supplement, click here to access the CME posttest

Program Director

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University School of Medicine
Director of Gynecological Ultrasound
Co-Director of Bone Densitometry
Department of Obstetrics and Gynecology
New York University Medical Center
New York, New York

Authors/Editors

Reni S. Butler, MD
Assistant Professor, Diagnostic Radiology
Yale University
New Haven, Connecticut

Bonnie N. Joe, MD, PhD, FSBI
Professor of Radiology and Biomedical Imaging
Chief, Breast Imaging
University of California, San Francisco
San Francisco, California

Bruce A. Porter, MD, FACR
Clinical Associate Professor
Department of Radiology
University of Washington School of Medicine
Seattle, Washington

Michael J. Ulissey, MD, FACR
Adjunct Professor of Radiology
University of Texas
Health Sciences Center
San Antonio, Texas
Breast Diagnostic Centers
Auburn and Federal Way, Washington

Conflict of Interest Disclosure

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Consultant: Cook OB/GYN, fees received
No Disclosures to Declare
Reni S. Butler, MD; Bonnie N. Joe, MD, PhD, FSBI;
Bruce A. Porter, MD, FACR; Michael J. Ulissey, MD, FACR;
Heidi M. Wilson, Course Director

Program Director

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University School of Medicine
Director of Gynecological Ultrasound
Co-Director of Bone Densitometry
Department of Obstetrics and Gynecology
New York University Medical Center
New York, New York

Authors/Editors

Reni S. Butler, MD
Assistant Professor, Diagnostic Radiology
Yale University
New Haven, Connecticut

Bonnie N. Joe, MD, PhD, FSBI
Professor of Radiology and Biomedical Imaging
Chief, Breast Imaging
University of California, San Francisco
San Francisco, California

Bruce A. Porter, MD, FACR
Clinical Associate Professor
Department of Radiology
University of Washington School of Medicine
Seattle, Washington

Michael J. Ulissey, MD, FACR
Adjunct Professor of Radiology
University of Texas
Health Sciences Center
San Antonio, Texas
Breast Diagnostic Centers
Auburn and Federal Way, Washington

Conflict of Interest Disclosure

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Consultant: Cook OB/GYN, fees received
No Disclosures to Declare
Reni S. Butler, MD; Bonnie N. Joe, MD, PhD, FSBI;
Bruce A. Porter, MD, FACR; Michael J. Ulissey, MD, FACR;
Heidi M. Wilson, Course Director

Program Director

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Professor of Obstetrics and Gynecology
New York University School of Medicine
Director of Gynecological Ultrasound
Co-Director of Bone Densitometry
Department of Obstetrics and Gynecology
New York University Medical Center
New York, New York

Authors/Editors

Reni S. Butler, MD
Assistant Professor, Diagnostic Radiology
Yale University
New Haven, Connecticut

Bonnie N. Joe, MD, PhD, FSBI
Professor of Radiology and Biomedical Imaging
Chief, Breast Imaging
University of California, San Francisco
San Francisco, California

Bruce A. Porter, MD, FACR
Clinical Associate Professor
Department of Radiology
University of Washington School of Medicine
Seattle, Washington

Michael J. Ulissey, MD, FACR
Adjunct Professor of Radiology
University of Texas
Health Sciences Center
San Antonio, Texas
Breast Diagnostic Centers
Auburn and Federal Way, Washington

Conflict of Interest Disclosure

Steven R. Goldstein, MD, CCD, NCMP, FACOG
Consultant: Cook OB/GYN, fees received
No Disclosures to Declare
Reni S. Butler, MD; Bonnie N. Joe, MD, PhD, FSBI;
Bruce A. Porter, MD, FACR; Michael J. Ulissey, MD, FACR;
Heidi M. Wilson, Course Director

Click here to read the Full Supplement

Click here to read the Full Supplement

Click here to read the Full Supplement

Click here to read the supplement

Click here to read the supplement

Click here to read the supplement

Family physicians are on the frontline for depression care, often being the first line of defense for diagnosis and management. This 1.25-hour, CME-certified activity will provide clinicians with a comprehensive review on the following:

• Clinical factors in the primary care setting that influence treatment outcomes in major depressive disorder
• Identification and management of residual symptoms
• Tools for effective monitoring of treatment outcomes
• Nonpharmacologic and pharmacologic therapies to treat patients to goal: remission and recovery
• Strategies to promote patient-focused, recovery-oriented care.

Click here to read the supplement.

After reading the supplement, click here to visit www.rapidcme.com/clinibriefs.aspx and complete the posttest and evaluation form for CME credit.

Family physicians are on the frontline for depression care, often being the first line of defense for diagnosis and management. This 1.25-hour, CME-certified activity will provide clinicians with a comprehensive review on the following:

• Clinical factors in the primary care setting that influence treatment outcomes in major depressive disorder
• Identification and management of residual symptoms
• Tools for effective monitoring of treatment outcomes
• Nonpharmacologic and pharmacologic therapies to treat patients to goal: remission and recovery
• Strategies to promote patient-focused, recovery-oriented care.

Click here to read the supplement.

After reading the supplement, click here to visit www.rapidcme.com/clinibriefs.aspx and complete the posttest and evaluation form for CME credit.

Family physicians are on the frontline for depression care, often being the first line of defense for diagnosis and management. This 1.25-hour, CME-certified activity will provide clinicians with a comprehensive review on the following:

• Clinical factors in the primary care setting that influence treatment outcomes in major depressive disorder
• Identification and management of residual symptoms
• Tools for effective monitoring of treatment outcomes
• Nonpharmacologic and pharmacologic therapies to treat patients to goal: remission and recovery
• Strategies to promote patient-focused, recovery-oriented care.

Click here to read the supplement.

After reading the supplement, click here to visit www.rapidcme.com/clinibriefs.aspx and complete the posttest and evaluation form for CME credit.